Type 2 diabetes mellitus (T2DM) is a progressive disease and early intervention and prevention strategies are therefore very important. An important early hallmark in the development of T2DM is insulin resistance. Since the majority of postprandial glucose disposal occurs in skeletal muscle, improving muscle insulin sensitivity will thus have a major impact on disease prevention. Abdominally obese men and women have an increased risk to develop T2DM, and are also characterized by an impaired vascular function. This may hamper proper delivery of insulin, glucose and oxygen to muscles, thereby contributing to - and possibly causing - muscle insulin resistance. Earlier it has been shown that supplementation with L- arginine improves vascular function by improving nitric oxide (NO) bioavailability. These NO- mediated beneficial effects on vascular function may improve delivery of insulin, glucose and oxygen to the muscle tissue, thereby improving muscle insulin sensitivity and mitochondrial function. However, the doses needed of this amino acid cannot be provided by regular diets or supplements, also due to the bitter taste of L-arginine. Alternatively, smaller amounts of L- arginine with a specific combination of other nutritional components (i.e. nitrate and nitrite), which are already part of the regular diet and support alternative pathways to improve NO- mediated vascular function, may also induce beneficial effects. The investigators now hypothesize that in abdominally obese adults with impaired fasting glucose concentrations L-arginine combined with nitrate/nitrite increases muscle insulin sensitivity.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Enrollment
1
Longer-term supplementation (8 weeks)
Longer-term supplementation (8 weeks)
Maastricht University Medical Center
Maastricht, Limburg, Netherlands
Change in insulin sensitivity
Muscle insulin sensitivity
Time frame: Change between 8-week placebo and 8-week intervention period
Change in muscle metabolism
Mitochondrial activity in muscle tissue
Time frame: Change between 8-week placebo and 8-week intervention period
Change in physical functioning (1)
6 meter walking test
Time frame: Change between 8-week placebo and 8-week intervention period
Change in physical functioning (2)
Timed up and go test
Time frame: Change between 8-week placebo and 8-week intervention period
Change in physical functioning (3)
Handgrip strength test
Time frame: Change between 8-week placebo and 8-week intervention period
Change in physical functioning (4)
Isokinetic muscle strength (BIODEX measurement)
Time frame: Change between 8-week placebo and 8-week intervention period
Change in vascular function (1)
Flow-mediated vasodilation of the brachial artery
Time frame: Change between 8-week placebo and 8-week intervention period
Change in vascular function (2)
Pulse wave analysis
Time frame: Change between 8-week placebo and 8-week intervention period
Change in vascular function (3)
Pulse wave velocity
Time frame: Change between 8-week placebo and 8-week intervention period
Change in vascular function (4)
Retinal microvascular calibers (Artery-to-Vein ratio)
Time frame: Change between 8-week placebo and 8-week intervention period
Change in cardiometabolic risk markers (1)
Plasma markers for low-grade systemic inflammation (CRP)
Time frame: Change between 8-week placebo and 8-week intervention period
Change in cardiometabolic risk markers (2)
Plasma markers for endothelial dysfunction (NOx)
Time frame: Change between 8-week placebo and 8-week intervention period
Change in cardiometabolic risk markers (3)
24-h Systolic and Diastolic blood pressure
Time frame: Change between 8-week placebo and 8-week intervention period
Change in continuous insulin sensitivity
36-h plasma glucose values
Time frame: Change between 8-week placebo and 8-week intervention period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.